This symposium reviews current cardiovascular outcomes data for PCSK9 inhibitors, how to integrate non-statin lipid-lowering therapies and current cholesterol guidelines for the management of high CV-risk patients, and strategies for gaining access to PCSK9 inhibitors for high CV risk patients that need them. In addition, attendees will have an opportunity to develop a treatment plan for real-world patients and compare and discuss their strategies with the faculty panel. Attendees are also encouraged to bring or submit difficult cases and questions to challenge the faculty in the “Stump the Faculty” segment.
P. Barton Duell, MD, FNLA, FAHA | Seth S. Martin, MD, MHS, FACC, FAHA, FASPC | Gregory Pokrywka, MD, FACP, FNLA, FASPC, NCMP
This event offers
2.0 CME credits
Accredited by Horizon CME is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation: Horizon CME designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ABIM MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit..